T Cell Non-Hodgkin Lymphoma Clinical Trial
Official title:
Safety and Efficacy of Anti-CD7 CAR-Engineered T Cells for Relapsed/Refractory T Lymphoid Malignancies: a Single-center, Open-label, Non-randomized, Single-arm Clinical Study
This is a single-center, open-label, single-arm study to evaluate the primary safety and efficacy of anti-CD7 chimeric antigen receptor(CAR)-modified T cells(CAR7-Ts) in patients with relapsed or refractory T lymphoid malignancies.
Chimeric antigen receptor-T cells (CAR-T) have made breakthroughs in the treatment of B-cell tumors, especially refractory/relapsed acute B lymphocytes. CD7 is a transmembrane glycoprotein expressed by T cells and natural killer cells and their precursors; it is also expressed in >95% of lymphoblastic T-cell leukemias and lymphomas . CD7 was previously evaluated as a target for immunotoxin-loaded antibodies in patients with T-cell malignancies, but tumor responses were limited. Enhancing the potency of CD7-directed cytotoxicity by substituting donor-derived CAR-T cells for a monoclonal antibody would augment the efficacy of CD7-targeted therapy in patients with T-cell malignancies. To prepare CAR7-T cells, CD7 expression is suppressed on donor-derived T cells by unique blocking technique, and CD7-negative T cells are transduced with a humanized anti-CD7-41BB-CD3ΞΆ lentiviral vector. This is an investigational study. The objectives are to evaluate the safety and efficacy of CAR7-T cells in patients with CD7+ T-cell malignancies. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05260203 -
MargheRITA (Remote Intelligence for Therapeutic Adherence)
|
N/A | |
| Not yet recruiting |
NCT06420089 -
CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
|
Phase 1 | |
| Completed |
NCT00684411 -
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
|
N/A | |
| Active, not recruiting |
NCT01908777 -
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
|
Phase 2 | |
| Recruiting |
NCT03590574 -
Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma
|
Phase 1/Phase 2 |